| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | María Chaparro | Q55602557 |
| P2093 | author name string | J Medina | |
| R Moreno-Otero | |||
| M Trapero-Marugán | |||
| L González Moreno | |||
| P2860 | cites work | Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. | Q31043193 |
| Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients | Q33503017 | ||
| Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma | Q33866067 | ||
| Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas | Q34380511 | ||
| Mechanisms of normal and tumor-derived angiogenesis | Q34592513 | ||
| P433 | issue | 11-12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| hepatocellular carcinoma | Q1148337 | ||
| P304 | page(s) | 1269-1277 | |
| P577 | publication date | 2008-09-20 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents | |
| P478 | volume | 28 |
| Q36140389 | Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer. |
| Q36729450 | HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. |
| Q36153539 | Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System |
| Q34131801 | Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting |
| Q28472011 | Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data |
| Q43569161 | Isolated fat-containing pancreatic metastasis from hepatocellular carcinoma |
| Q89799519 | LINC00978 promotes hepatocellular carcinoma carcinogenesis partly via activating the MAPK/ERK pathway |
| Q35541482 | Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview |
| Q39431960 | Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways |
| Q51747220 | Outcome of supraselective transarterial chemoembolization in patients with hepatocellular carcinoma |
| Q39615186 | PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways |
| Q37545879 | Potential of Radiofrequency Ablation in Combination with Immunotherapy in the Treatment of Hepatocellular Carcinoma |
| Q43411812 | Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib |
| Q34704781 | Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors |
| Q38734040 | Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma |
| Q39030388 | Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. |
| Q28235646 | Sorafenib: a review of its use in advanced hepatocellular carcinoma |
| Q37827878 | Sorafenib: activity and clinical application in patients with hepatocellular carcinoma |
| Q37481085 | TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. |
| Q36929326 | The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma |
| Q37253389 | The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma |
| Q28540521 | The study of a novel sorafenib derivative HLC-080 as an antitumor agent |
| Q56970979 | Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis |
Search more.